Omeros CorpNASDAQ:OMER
- LAST PRICE4.0600
- TODAY'S CHANGE (%)0.1100 (2.7848%)
- Bid / Lots3.7500/ 1
- Ask / Lots4.2000/ 10
- Open / Previous Close3.9900 / 3.9500
- Day Range
- 52 Week Range
- Volume688,888
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 1925 | 3.99 |
| 09:36 ET | 1000 | 4 |
| 09:39 ET | 474 | 4.04 |
| 09:41 ET | 1071 | 4.04 |
| 09:43 ET | 2793 | 4 |
| 10:01 ET | 800 | 3.985 |
| 10:08 ET | 1800 | 3.98 |
| 10:10 ET | 625 | 3.985 |
| 10:17 ET | 100 | 4 |
| 10:19 ET | 183 | 3.99 |
| 10:26 ET | 200 | 4 |
| 10:32 ET | 405 | 4.003 |
| 10:35 ET | 300 | 3.98 |
| 11:00 ET | 100 | 3.98 |
| 11:02 ET | 700 | 3.96 |
| 11:06 ET | 100 | 3.95 |
| 11:08 ET | 5100 | 3.9403 |
| 11:13 ET | 320 | 3.93 |
| 11:18 ET | 789 | 3.94 |
| 11:31 ET | 1017 | 3.93 |
| 11:40 ET | 1125 | 3.93 |
| 11:45 ET | 1939 | 3.92 |
| 11:51 ET | 200 | 3.935 |
| 12:02 ET | 5500 | 3.95 |
| 12:09 ET | 926 | 3.92 |
| 12:16 ET | 100 | 3.92 |
| 12:20 ET | 2526 | 3.92 |
| 12:30 ET | 300 | 3.93 |
| 12:34 ET | 11397 | 3.94 |
| 12:36 ET | 100 | 3.925 |
| 12:43 ET | 100 | 3.925 |
| 12:54 ET | 4052 | 3.92 |
| 12:59 ET | 100 | 3.93 |
| 01:01 ET | 300 | 3.92 |
| 01:03 ET | 100 | 3.92 |
| 01:08 ET | 400 | 3.92 |
| 01:10 ET | 3429 | 3.95 |
| 01:12 ET | 250 | 3.9435 |
| 01:15 ET | 600 | 3.94 |
| 01:17 ET | 100 | 3.94 |
| 01:19 ET | 100 | 3.94 |
| 01:24 ET | 100 | 3.94 |
| 01:28 ET | 700 | 3.94 |
| 01:32 ET | 100 | 3.94 |
| 01:33 ET | 100 | 3.95 |
| 01:35 ET | 300 | 3.94 |
| 01:37 ET | 500 | 3.94 |
| 01:39 ET | 400 | 3.94 |
| 01:50 ET | 400 | 3.9401 |
| 01:51 ET | 846 | 3.94 |
| 01:53 ET | 100 | 3.94 |
| 01:57 ET | 200 | 3.94 |
| 02:02 ET | 931 | 3.94 |
| 02:06 ET | 300 | 3.94 |
| 02:08 ET | 100 | 3.94 |
| 02:09 ET | 300 | 3.94 |
| 02:11 ET | 248 | 3.944 |
| 02:18 ET | 100 | 3.945 |
| 02:20 ET | 104 | 3.9412 |
| 02:27 ET | 200 | 3.94 |
| 02:31 ET | 400 | 3.94 |
| 02:36 ET | 2527 | 3.95 |
| 02:38 ET | 1000 | 3.9529 |
| 02:42 ET | 2626 | 3.97 |
| 02:44 ET | 417 | 3.96 |
| 02:49 ET | 100 | 3.9503 |
| 02:51 ET | 100 | 3.95 |
| 02:54 ET | 100 | 3.95 |
| 02:58 ET | 300 | 3.945 |
| 03:00 ET | 300 | 3.945 |
| 03:03 ET | 500 | 3.94 |
| 03:05 ET | 100 | 3.93 |
| 03:07 ET | 211 | 3.925 |
| 03:09 ET | 1557 | 3.92 |
| 03:12 ET | 300 | 3.92 |
| 03:14 ET | 1026 | 3.92 |
| 03:16 ET | 1374 | 3.92 |
| 03:18 ET | 729 | 3.92 |
| 03:21 ET | 1278 | 3.93 |
| 03:23 ET | 300 | 3.9239 |
| 03:25 ET | 2970 | 3.92 |
| 03:30 ET | 971 | 3.92 |
| 03:32 ET | 759 | 3.92 |
| 03:34 ET | 400 | 3.92 |
| 03:36 ET | 1690 | 3.92 |
| 03:39 ET | 200 | 3.93 |
| 03:41 ET | 100 | 3.925 |
| 03:43 ET | 100 | 3.92 |
| 03:45 ET | 4526 | 3.92 |
| 03:48 ET | 400 | 3.92 |
| 03:50 ET | 400 | 3.92 |
| 03:52 ET | 55377 | 4.025 |
| 03:54 ET | 10060 | 4.06 |
| 03:56 ET | 6471 | 4.04 |
| 03:57 ET | 1200 | 4.04 |
| 03:59 ET | 6779 | 4.06 |
Jun 4, 2024
Omeros Announces Webcast Details for Annual Meeting of Shareholders, from 9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Omeros Shares Rise on Balance Sheet Strengthening, from 11:33AM ET on Monday Jun 03, 2024 by Dow Jones
11:33AM ET on Monday Jun 03, 2024 by Dow JonesOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028, from 9:00AM ET on Monday Jun 03, 2024 by Dow Jones
9:00AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 235.3M | -1.4x | --- |
ESSA Pharma Inc | 233.3M | -8.4x | --- |
Tectonic Therapeutic Inc | 242.7M | 2.0x | --- |
Monte Rosa Therapeutics Inc | 227.5M | -1.5x | --- |
Tenaya Therapeutics Inc | 243.4M | -1.9x | --- |
Skye Bioscience Inc | 224.8M | -1.8x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance
- Michael Jacobsen
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $235.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-2.90 |
Book Value | $-0.41 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
